Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy

T. Jared Bunch, Thomas M. Munger, Paul Andrew Friedman, Samuel J Asirvatham, Peter A. Brady, Yong-Mei Cha, Robert F. Rea, Win Kuang Shen, Brian D. Powell, Steve R. Ommen, Kristi H. Monahan, Janis M. Haroldson, Douglas L Packer

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Substrate and Procedural Predictors of Outcome in Patients with Hypertrophic Cardiomyopathy. Background: Hypertrophic cardiomyopathy (HCM) is often accompanied by atrial fibrillation (AF) due to diastolic dysfunction, elevated left atrial pressure, and enlargement. Although catheter ablation for drug-refractory AF is an effective treatment, the efficacy in HCM remains to be established. Methods: Thirty-three consecutive patients (25 male, age 51 ± 11 years) with HCM underwent pulmonary vein (PV) isolation (n = 8) or wide area circumferential ablation with additional linear ablation (n = 25) for drug-refractory AF. Twelve-lead and 24-hour ambulating ECGs, echocardiograms, event monitor strips, and SF 36 quality of life (QOL) surveys were obtained before ablation and for routine follow-up. Results: Twenty-one (64%) patients had paroxysmal AF and 12 (36%) had persistent/permanent AF for 6.2 ± 5.2 years. The average ejection fraction was 0.63 ± 0.12. The average left atrial volume index was 70 ± 24 mL/m2. Over a follow-up of 1.5 ± 1.2 years, 1-year survival with AF elimination was 62%(Confidence Interval [CI]: 66-84) and with AF control was 75%(CI: 66-84). AF control was less likely in patients with a persistent/chronic AF, larger left atrial volumes, and more advanced diastolic disease. Additional linear ablation may improve outcomes in patient with severe left atrial enlargement and more advanced diastolic dysfunction. Two patients had a periprocedureal TIA, one PV stenosis, and one died after mitral valve replacement from prosthetic valve thrombosis. QOL scores improved from baseline at 3 and 12 months. Conclusion: Outcomes after AF ablation in patients with HCM are favorable. Diastolic dysfunction, left atrial enlargement, and AF subtype influence outcomes. Future studies of rhythm management approaches in HCM patients are required to clarify the optimal clinical approach.

Original languageEnglish (US)
Pages (from-to)1009-1014
Number of pages6
JournalJournal of Cardiovascular Electrophysiology
Volume19
Issue number10
DOIs
StatePublished - Oct 2008

Fingerprint

Catheter Ablation
Hypertrophic Cardiomyopathy
Atrial Fibrillation
Quality of Life
Confidence Intervals
Atrial Pressure
Pulmonary Veins
Mitral Valve
Pharmaceutical Preparations
Electrocardiography
Thrombosis

Keywords

  • Atrial fibrillation
  • Catheter ablation
  • Diastole
  • Heart atrium
  • Hypertrophic cardiomyopathy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. / Bunch, T. Jared; Munger, Thomas M.; Friedman, Paul Andrew; Asirvatham, Samuel J; Brady, Peter A.; Cha, Yong-Mei; Rea, Robert F.; Shen, Win Kuang; Powell, Brian D.; Ommen, Steve R.; Monahan, Kristi H.; Haroldson, Janis M.; Packer, Douglas L.

In: Journal of Cardiovascular Electrophysiology, Vol. 19, No. 10, 10.2008, p. 1009-1014.

Research output: Contribution to journalArticle

Bunch, T. Jared ; Munger, Thomas M. ; Friedman, Paul Andrew ; Asirvatham, Samuel J ; Brady, Peter A. ; Cha, Yong-Mei ; Rea, Robert F. ; Shen, Win Kuang ; Powell, Brian D. ; Ommen, Steve R. ; Monahan, Kristi H. ; Haroldson, Janis M. ; Packer, Douglas L. / Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. In: Journal of Cardiovascular Electrophysiology. 2008 ; Vol. 19, No. 10. pp. 1009-1014.
@article{a4d3784c718e41318185a4ed98edcee5,
title = "Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy",
abstract = "Substrate and Procedural Predictors of Outcome in Patients with Hypertrophic Cardiomyopathy. Background: Hypertrophic cardiomyopathy (HCM) is often accompanied by atrial fibrillation (AF) due to diastolic dysfunction, elevated left atrial pressure, and enlargement. Although catheter ablation for drug-refractory AF is an effective treatment, the efficacy in HCM remains to be established. Methods: Thirty-three consecutive patients (25 male, age 51 ± 11 years) with HCM underwent pulmonary vein (PV) isolation (n = 8) or wide area circumferential ablation with additional linear ablation (n = 25) for drug-refractory AF. Twelve-lead and 24-hour ambulating ECGs, echocardiograms, event monitor strips, and SF 36 quality of life (QOL) surveys were obtained before ablation and for routine follow-up. Results: Twenty-one (64{\%}) patients had paroxysmal AF and 12 (36{\%}) had persistent/permanent AF for 6.2 ± 5.2 years. The average ejection fraction was 0.63 ± 0.12. The average left atrial volume index was 70 ± 24 mL/m2. Over a follow-up of 1.5 ± 1.2 years, 1-year survival with AF elimination was 62{\%}(Confidence Interval [CI]: 66-84) and with AF control was 75{\%}(CI: 66-84). AF control was less likely in patients with a persistent/chronic AF, larger left atrial volumes, and more advanced diastolic disease. Additional linear ablation may improve outcomes in patient with severe left atrial enlargement and more advanced diastolic dysfunction. Two patients had a periprocedureal TIA, one PV stenosis, and one died after mitral valve replacement from prosthetic valve thrombosis. QOL scores improved from baseline at 3 and 12 months. Conclusion: Outcomes after AF ablation in patients with HCM are favorable. Diastolic dysfunction, left atrial enlargement, and AF subtype influence outcomes. Future studies of rhythm management approaches in HCM patients are required to clarify the optimal clinical approach.",
keywords = "Atrial fibrillation, Catheter ablation, Diastole, Heart atrium, Hypertrophic cardiomyopathy",
author = "Bunch, {T. Jared} and Munger, {Thomas M.} and Friedman, {Paul Andrew} and Asirvatham, {Samuel J} and Brady, {Peter A.} and Yong-Mei Cha and Rea, {Robert F.} and Shen, {Win Kuang} and Powell, {Brian D.} and Ommen, {Steve R.} and Monahan, {Kristi H.} and Haroldson, {Janis M.} and Packer, {Douglas L}",
year = "2008",
month = "10",
doi = "10.1111/j.1540-8167.2008.01192.x",
language = "English (US)",
volume = "19",
pages = "1009--1014",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy

AU - Bunch, T. Jared

AU - Munger, Thomas M.

AU - Friedman, Paul Andrew

AU - Asirvatham, Samuel J

AU - Brady, Peter A.

AU - Cha, Yong-Mei

AU - Rea, Robert F.

AU - Shen, Win Kuang

AU - Powell, Brian D.

AU - Ommen, Steve R.

AU - Monahan, Kristi H.

AU - Haroldson, Janis M.

AU - Packer, Douglas L

PY - 2008/10

Y1 - 2008/10

N2 - Substrate and Procedural Predictors of Outcome in Patients with Hypertrophic Cardiomyopathy. Background: Hypertrophic cardiomyopathy (HCM) is often accompanied by atrial fibrillation (AF) due to diastolic dysfunction, elevated left atrial pressure, and enlargement. Although catheter ablation for drug-refractory AF is an effective treatment, the efficacy in HCM remains to be established. Methods: Thirty-three consecutive patients (25 male, age 51 ± 11 years) with HCM underwent pulmonary vein (PV) isolation (n = 8) or wide area circumferential ablation with additional linear ablation (n = 25) for drug-refractory AF. Twelve-lead and 24-hour ambulating ECGs, echocardiograms, event monitor strips, and SF 36 quality of life (QOL) surveys were obtained before ablation and for routine follow-up. Results: Twenty-one (64%) patients had paroxysmal AF and 12 (36%) had persistent/permanent AF for 6.2 ± 5.2 years. The average ejection fraction was 0.63 ± 0.12. The average left atrial volume index was 70 ± 24 mL/m2. Over a follow-up of 1.5 ± 1.2 years, 1-year survival with AF elimination was 62%(Confidence Interval [CI]: 66-84) and with AF control was 75%(CI: 66-84). AF control was less likely in patients with a persistent/chronic AF, larger left atrial volumes, and more advanced diastolic disease. Additional linear ablation may improve outcomes in patient with severe left atrial enlargement and more advanced diastolic dysfunction. Two patients had a periprocedureal TIA, one PV stenosis, and one died after mitral valve replacement from prosthetic valve thrombosis. QOL scores improved from baseline at 3 and 12 months. Conclusion: Outcomes after AF ablation in patients with HCM are favorable. Diastolic dysfunction, left atrial enlargement, and AF subtype influence outcomes. Future studies of rhythm management approaches in HCM patients are required to clarify the optimal clinical approach.

AB - Substrate and Procedural Predictors of Outcome in Patients with Hypertrophic Cardiomyopathy. Background: Hypertrophic cardiomyopathy (HCM) is often accompanied by atrial fibrillation (AF) due to diastolic dysfunction, elevated left atrial pressure, and enlargement. Although catheter ablation for drug-refractory AF is an effective treatment, the efficacy in HCM remains to be established. Methods: Thirty-three consecutive patients (25 male, age 51 ± 11 years) with HCM underwent pulmonary vein (PV) isolation (n = 8) or wide area circumferential ablation with additional linear ablation (n = 25) for drug-refractory AF. Twelve-lead and 24-hour ambulating ECGs, echocardiograms, event monitor strips, and SF 36 quality of life (QOL) surveys were obtained before ablation and for routine follow-up. Results: Twenty-one (64%) patients had paroxysmal AF and 12 (36%) had persistent/permanent AF for 6.2 ± 5.2 years. The average ejection fraction was 0.63 ± 0.12. The average left atrial volume index was 70 ± 24 mL/m2. Over a follow-up of 1.5 ± 1.2 years, 1-year survival with AF elimination was 62%(Confidence Interval [CI]: 66-84) and with AF control was 75%(CI: 66-84). AF control was less likely in patients with a persistent/chronic AF, larger left atrial volumes, and more advanced diastolic disease. Additional linear ablation may improve outcomes in patient with severe left atrial enlargement and more advanced diastolic dysfunction. Two patients had a periprocedureal TIA, one PV stenosis, and one died after mitral valve replacement from prosthetic valve thrombosis. QOL scores improved from baseline at 3 and 12 months. Conclusion: Outcomes after AF ablation in patients with HCM are favorable. Diastolic dysfunction, left atrial enlargement, and AF subtype influence outcomes. Future studies of rhythm management approaches in HCM patients are required to clarify the optimal clinical approach.

KW - Atrial fibrillation

KW - Catheter ablation

KW - Diastole

KW - Heart atrium

KW - Hypertrophic cardiomyopathy

UR - http://www.scopus.com/inward/record.url?scp=52049100334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52049100334&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8167.2008.01192.x

DO - 10.1111/j.1540-8167.2008.01192.x

M3 - Article

C2 - 18479329

AN - SCOPUS:52049100334

VL - 19

SP - 1009

EP - 1014

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 10

ER -